CHRM4 and prostate carcinoma: These results suggest that interactions between prostate cancer cells and M2c macrophages may drive the immunosuppressive TME, where increased IFNA17 and CHRM4 levels may promote NEPC differentiation and immune checkpoint abundance in prostate cancer cells.